Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...

Bioequivalence studies: Biowaivers

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

Drug Dosing: Infants and Children

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Is Maternal Diabetes Mellitus Type 2 a Protective Factor for Atopic Dermatitis in Children? A Nationwide Retrospective Cohort Study.

Dermatitis : contact, atopic, occupational, drug·2026

Same author

Cell-free DNA Levels in Cellulitis: A Cross-sectional Prospective Study.

Acta dermato-venereologica·2026

Same author

Noninvasive Skin Surface Sampling Identifies Elevated IL-1β and IL-6 in Paediatric Atopic Dermatitis Patients.

Acta dermato-venereologica·2026

Same author

Gestational Diabetes Mellitus Increases the Risk of Atopic Dermatitis in Children: A National Retrospective Study with Analysis by Treatment Modality.

Dermatology and therapy·2026

Same author

Comorbidities and Healthcare Utilization in 4197 Patients With Prurigo Nodularis in Israel: A Cross-Sectional Population-Based Analysis.

International journal of dermatology·2025

Same author

Evaluating the Quality of TikTok Videos on Vitiligo: A Cross-Sectional Study.

International journal of dermatology·2025

Same journal

The Relationship Between Melanoma Subtype and Organ-Specific Metastases: An Observational Study.

Annals of dermatology·2026

Same journal

The Upgrading Clinical Subtype Classification of Basal Cell Carcinoma is Useful to Correlate With Its Histologic Subtype and Local Invasiveness.

Annals of dermatology·2026

Same journal

Clinical Efficacy and Scalp Microbiome Changes Induced by AMPamide-Containing Shampoo in Patients With Seborrheic Dermatitis.

Annals of dermatology·2026

Same journal

Effects of Botulinum Toxin A on Rosacea-Like Inflammation in an LL-37-Induced Rosacea Mouse Model.

Annals of dermatology·2026

Same journal

Clinical Importance of Autoantibodies to SOX10 and Lamin A/C as Potential Biomarkers in Sera From Vitiligo Patients.

Annals of dermatology·2026

Same journal

A 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitor, 11b-0048, Effectively Suppresses the Expression of 11β-HSD1 Activated in Cultured Keratinocytes and in Diabetic Murine Skin.

Annals of dermatology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Crisaborole 2% for Pediatric Periorificial Dermatitis: A Randomized, Double-Blind, Vehicle-Controlled Pilot Study.

Ayelet Ollech¹, Bat-El Bar Aluma², Adi Weiss-Fink³

¹Pediatric Dermatology Service, Shaare Zedek Medical Center, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. ayeletol@szmc.org.il.

Annals of Dermatology

|June 5, 2026

Summary

This summary is machine-generated.

Topical crisaborole did not show statistically significant improvement over placebo for pediatric periorificial dermatitis (POD) in a small pilot study. Further research is needed to confirm the efficacy of this phosphodiesterase 4 (PDE4) inhibitor for POD treatment.

Keywords:

Eczematous skin diseases Non-steroidal anti-inflammatory agent Pediatrics Perioral dermatitis Phosphodiesterase inhibitors

More Related Videos

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

Related Experiment Videos

Last Updated: Jun 6, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

Area of Science:

Dermatology
Pediatrics
Pharmacology

Background:

Periorificial dermatitis (POD) is a common inflammatory skin condition affecting infants, children, and young women.
Phosphodiesterase 4 (PDE4) inhibitors represent a novel, non-steroidal anti-inflammatory treatment approach for POD.

Purpose of the Study:

To evaluate the efficacy and safety of topical crisaborole 2% ointment, a PDE4 inhibitor, in treating pediatric patients with POD.

Main Methods:

A randomized, double-blind, vehicle-controlled trial involving 23 pediatric participants (3 months to 18 years).
Treatment with crisaborole 2% ointment or placebo for 4 weeks, followed by a 4-week observation period.
Primary endpoints included a 50% reduction in Perioral Dermatitis Severity Index (PODSI) and Investigator's Global Assessment (IGA) score of 0 or 1 by day 14.

Main Results:

Both crisaborole and placebo groups showed improvement in PODSI and IGA scores.
No statistically significant differences were observed between the crisaborole and placebo groups at any time point.
Mild burning or stinging was reported more frequently with crisaborole but was generally tolerable.

Conclusions:

Crisaborole demonstrated a modest numerical trend favoring improvement but was not statistically superior to placebo in this pilot study.
Larger studies are required to further validate the efficacy of crisaborole for treating periorificial dermatitis.